FrontMatter -- Contents -- Preface -- Executive Summary -- 1 Introduction and Background -- 2 Clinical Trials -- 3 Treatment, Financing, and Costs -- 4 Behavioral Responses and Consent -- References -- Appendixes -- A Vaccines and Depot Medications for Drug Addiction: Rationale, Mechanisms of Action, and Treatment Implications--Paul R. Pentel -- B What Will We Learn from the FDA Clinical Trials Process and What Will We Still Want to Know About Immunotherapies and Depot Medications to Treat Drug Dependence?--Thomas R. Kosten and Henry R. Kranzler -- C Putting Addiction Treatment Medications to Use: Lessons Learned--George E. Woody and Laura McNicholas -- D Adoption of Drug Abuse Treatment Technology in Specialty and Primary Care Settings--Cindy Parks Thomas and Dennis McCarty -- E The Use of Immunotherapies and Sustained-Release Formulations in the Treatment of Drug Addiction: Will Current Law Support Coercion?--M. Susan Ridgely, Martin Y. Iguchi, and James R. Chiesa -- F Ethical Issues in Immunotherapies and Depot Medications for Substance Abuse--Thomas H. Murray -- G Costs and Benefits of Immunotherapies or Depot Medications for the Treatment of Drug Abuse--Mark A.R. Kleiman -- H Anticipating Unintended Consequences of Vaccine-Like Immunotherapies and Depot Medications for Addictive Drug Use--Robert J. MacCoun -- I Vaccines and Immunotherapies to Control Addiction in Minors: The Legal Framework--Frances H. Miller and Kaley Klanica -- J Biographical Sketches of Committee Members and Staff.